| Paroxysmal nocturnal hemoglobinuria
Empaveli vs Fabhalta
Side-by-side clinical, coverage, and cost comparison for paroxysmal nocturnal hemoglobinuria.Deep comparison between: Empaveli vs Fabhalta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFabhalta has a higher rate of injection site reactions vs Empaveli based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Fabhalta but not Empaveli, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Empaveli
Fabhalta
At A Glance
SC injection
Twice weekly
C3 complement inhibitor
Oral
Twice daily
Factor B inhibitor
Indications
- Paroxysmal nocturnal hemoglobinuria
- C3 glomerulopathy
- Immune-complex membranoproliferative glomerulonephritis
- Paroxysmal nocturnal hemoglobinuria
- IGA Glomerulonephritis
- Complement 3 Glomerulopathies
Dosing
Paroxysmal nocturnal hemoglobinuria 1,080 mg SC twice weekly; adjust to 1,080 mg every three days if LDH >2x ULN.
C3 glomerulopathy, Immune-complex membranoproliferative glomerulonephritis Adults: 1,080 mg SC twice weekly; pediatric patients (12 to <18 years): weight-based dosing from 648 mg to 1,080 mg SC twice weekly based on body weight.
Paroxysmal nocturnal hemoglobinuria, IGA Glomerulonephritis, Complement 3 Glomerulopathies 200 mg orally twice daily without regard to food; swallow capsules whole.
PNH Patients Switching From Anti-C5 Initiate FABHALTA no later than 1 week after last eculizumab dose or no later than 6 weeks after last ravulizumab dose.
Contraindications
- Hypersensitivity to pegcetacoplan or any excipient
- Unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B
- Serious hypersensitivity to iptacopan or any of the excipients
- Unresolved serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type b (contraindicated for initiation)
Adverse Reactions
Most common (>=10%) Injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, fatigue
Serious Infections, intestinal ischemia, biliary sepsis, hypersensitivity pneumonitis
Postmarketing Anaphylaxis, urticaria
Most common (>=10%) headache, nasopharyngitis, diarrhea, abdominal pain, bacterial infection, viral infection, nausea, rash
Serious serious infections caused by encapsulated bacteria, hyperlipidemia
Pharmacology
C3 complement inhibitor; pegcetacoplan binds complement protein C3 and its activation fragment C3b, regulating downstream complement activation to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in PNH, and to inhibit C3 glomerular fragment deposition and C5b-9 assembly in C3G and primary IC-MPGN.
Factor B inhibitor; iptacopan binds to Factor B of the alternative complement pathway, regulating C3 cleavage and inhibiting downstream effectors to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis in PNH, and to inhibit complement-driven glomerular injury in IgAN and C3G.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Empaveli
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Fabhalta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Empaveli
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Fabhalta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Empaveli
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Fabhalta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableApellis Bridge Program: Empaveli
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Immunoglobulin A Nephropathy (IgAN)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EmpaveliView full Empaveli profile
FabhaltaView full Fabhalta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.